Clinical Trials on Glabellar Frown Lines in Spain

Total 13 results

Teoxane SA

Active, not recruiting

TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines

Skin Aging | Fine Lines of the Face and Neck

Spain
University of Valencia
University Hospital, Caen

Recruiting

Creation and Validation of a Questionnaire Evaluating Diastasis Recti (QUEDIA)

Diastasis Recti | Diastasis Recti and Weakness of the Linea Alba

Spain
Mayne Pharma International Pty Ltd

Terminated

A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

Lamellar Ichthyosis

United States, Spain, Canada, Germany, France, Australia, Israel, Ukraine, United Kingdom
PharmaMar

Completed

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Neuroendocrine Tumors | Endometrial Adenocarcinomas | Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy

Spain, United Kingdom
LeMaitre Vascular
Factory CRO for Medical Devices B.V.

Recruiting

Prospective and Non-randomized Registry of CardioCel 3D

Intracardiac and Septal Defects | Valve and Anulus Repair | Great Vessel Reconstruction | Peripheral Vessel Reconstruction | Suture Line Buttressing

Germany, Italy, Spain, United Kingdom
Novartis Pharmaceuticals

Completed

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

3rd Line GIST

Italy, Belgium, Spain, Netherlands, Germany, United Kingdom, France, United States
Novartis Pharmaceuticals

Completed

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

3rd Line GIST

France, United Kingdom, Belgium, Canada, Spain, Netherlands, Japan, United States
Grupo Oncológico para el Tratamiento y el Estudio...

Unknown

Trial of Rituximab, Bendamustine (RB) for Patients With Follicular Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line

Follicular Non-Hodgking´s Lymphoma Refractory or Relapsed After Treatment With R-chemotherapy in First Line.

Spain
Novartis Pharmaceuticals

Completed

A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer

Endometrial Cancer | VEGF | Solid Tumors and Advanced Endometrial Cancer | Second-line Treatment

Italy, United Kingdom, Spain, Brazil, United States, Korea, Republic of, New Zealand
Genzyme, a Sanofi Company

Completed

A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). (PREDICT)

Transplantation | Lymphoma (Non-Hodgkin's Lymphoma) | Hodgkin's Disease or Multiple Myeloma | Front Line Mobilization

Netherlands, France, Germany, Sweden, Spain, Italy, United Kingdom
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in First-line NSCLC (JAVELIN Lung 100)

First Line Non-Small Cell Lung Cancer

Spain, United States, Hungary, Israel, China, Korea, Republic of, Taiwan, Czechia, Russian Federation, Australia, Brazil, Lebanon, Serbia, Thailand, Canada, Slovakia, Ukraine, Bulgaria, Italy, Netherlands, New Zealand, Poland, Belgium, Turk... and more
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third Line

Spain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
AstraZeneca
Merck Sharp & Dohme LLC; GOG Foundation; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. (SOLO-1)

Advanced Ovarian Cancer | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response | BRCA Mutation | First Line Platinum Chemotherapy

Korea, Republic of, France, Italy, United States, Israel, Canada, China, Brazil, United Kingdom, Poland, Australia, Japan, Netherlands, Russian Federation, Spain

Clinical Trials on Glabellar Frown Lines in Spain

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations